Advances in Cancer Research: Targeting RAS Oncoprotein

By John P. O’Bryan, Author

Volume 153: A Comprehensive Review of RAS Oncoprotein Biology and Therapeutic Targeting

2021 marked a significant milestone in cancer research with the approval of the first direct RAS inhibitor, sotorasib, for treating non-small cell lung cancers harboring KRAS(G12C) mutations. This breakthrough highlights that the once elusive RAS oncoprotein is now pharmacologically tractable. This volume provides an in-depth overview of ongoing efforts to develop additional approaches to therapeutically target oncogenic RAS.

A Brief History of RAS Research and Development

The journey to understand and pharmacologically inhibit RAS has been long and challenging. This section delves into the history of RAS research, from its initial discovery to the current state-of-the-art approaches in anti-RAS therapies.

Understanding RAS Mutants: Biochemistry and Oncogenic Activity

Different RAS mutant proteins exhibit distinct biochemistry and oncogenic activities. This section explores these differences and how they can be leveraged in the development of effective anti-RAS therapies.

Cutting-Edge Approaches to Anti-RAS Pharmacologics

This section presents up-to-date reviews on the latest approaches to develop new anti-RAS drugs. It covers various strategies, including direct RAS inhibitors, RAS-effector interactions, and RAS-related signaling pathways.

Product Details

Publisher: Elsevier Science

Publication Date: January 29, 2022

Language: English

ISBN: 9780128244852, 9780128244869